NASDAQ:NVIV - Invivo Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.58 0.00 (0.00 %)
(As of 01/21/2019 04:00 PM ET)
Previous Close$1.58
Today's Range$1.55 - $1.6297
52-Week Range$1.36 - $24.50
Volume23,321 shs
Average Volume38,822 shs
Market Capitalization$14.70 million
P/E Ratio-0.09
Dividend YieldN/A
Beta1.77
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.

Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVIV
CUSIPN/A
Phone617-863-5500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$7.37 per share

Profitability

Net Income$-26,740,000.00

Miscellaneous

Employees12
Market Cap$14.70 million
OptionableNot Optionable

Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

What is Invivo Therapeutics' stock symbol?

Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work?

Invivo Therapeutics shares reverse split on Tuesday, April 17th 2018. The 1-25 reverse split was announced on Monday, April 9th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 16th 2018. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 4 shares after the split.

How were Invivo Therapeutics' earnings last quarter?

Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) released its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported ($0.42) earnings per share for the quarter. View Invivo Therapeutics' Earnings History.

When is Invivo Therapeutics' next earnings date?

Invivo Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for Invivo Therapeutics.

Has Invivo Therapeutics been receiving favorable news coverage?

Media headlines about NVIV stock have trended very positive on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Invivo Therapeutics earned a news impact score of 3.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are some of Invivo Therapeutics' key competitors?

Who are Invivo Therapeutics' key executives?

Invivo Therapeutics' management team includes the folowing people:
  • Dr. Richard M. Toselli, Pres, CEO, Principal Financial Officer, Chief Medical Officer & Director (Age 61)
  • Dr. Robert S. Langer Jr., Co-Founder and Member of Scientific Advisory Board (Age 69)
  • Dr. Joseph Philip Vacanti, Co-Founder (Age 69)
  • Mr. William D'Agostino PE, Sr. VP of Operations
  • Mr. Phil Pereira, Director of Manufacturing

How do I buy shares of Invivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Invivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $1.58.

How big of a company is Invivo Therapeutics?

Invivo Therapeutics has a market capitalization of $14.70 million. The biotechnology company earns $-26,740,000.00 in net income (profit) each year or ($18.50) on an earnings per share basis. Invivo Therapeutics employs 12 workers across the globe.

What is Invivo Therapeutics' official website?

The official website for Invivo Therapeutics is http://www.invivotherapeutics.com.

How can I contact Invivo Therapeutics?

Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected]


MarketBeat Community Rating for Invivo Therapeutics (NASDAQ NVIV)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  150 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  250
MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote "Outperform" if you believe NVIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: Backdoor Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel